Zofran and generics (ondansetron) - Important Safety Information from GlaxoSmithKline as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 09/08/2012

Important Safety Information communication from GlaxoSmithKline on ondansetron (Zofran and generics) and dose-dependent QT interval prolongation – new dose restriction for intravenous (IV) use.

Important Safety Information - Zofran and generics

Summary of Product Characteristics

Package Leaflet: Information for the User